Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns

Hannan M. Braun, Jury Candelario, Courtney L. Hanlon, Eddy R. Segura, Jesse L. Clark, Judith S. Currier, Jordan E. Lake

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.

Original languageEnglish
Pages (from-to)371-375
Number of pages5
JournalLGBT Health
Volume4
Issue number5
DOIs
StatePublished - Oct 2017
Externally publishedYes

Keywords

  • HIV
  • antiretroviral therapy
  • health disparities
  • medication adherence
  • transgender

Fingerprint

Dive into the research topics of 'Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns'. Together they form a unique fingerprint.

Cite this